Picture [iito] Back into Ad 650x80px
Document › Details

ThromboGenics N.V.. (9/21/17). "Press Release: ThromboGenics Provides Business and Clinical Update at European and US Investor Meetings". Leuven.

Region Region Basel BS
  Country Switzerland
Organisations Organisation ThromboGenics N.V. (Euronext Brussels: THR)
  Today Oxurion N.V. (Euronext Brussels: OXUR)
  Group Oxurion (Group)
  Organisation 2 Sachs Associates Ltd.
Products Product Sachs Annual Biotech in Europe Forum 2017 Basel
  Product 2 KBC Securities Benelux Biotech & Healthcare Conference 2017 New York
Index terms Index term ThromboGenics–KBC: investor conference, 201709 supply service ThromboGenics presents at KBC Securities Biotech & Healthcare Conference in NY
  Index term 2 ThromboGenics–EZIL: investor conference, 201710 supply service IntegraGen participates at European Large & Midcap Event in Paris
Persons Person Piepers, Wouter (ThromboGenics 201303 Global Head Corporate Communications)
  Person 2 Dible, David (Huntsworth 201506 Senior Director Life Sciences at Citigate Dewe Rogerson London)

ThromboGenics NV (Euronext Brussels: THR), biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, today announced that it will be provide business and clinical updates at a number of key investor meetings over the next few months.

> Sachs Annual Biotech in Europe Forum 2017, Basel, Switzerland – Meetings and presentation on 26 Sep 2017

> KBC Securities, Biotech & Healthcare Conference, New York, US – Meetings and presentation on 28 Sep 2017

> VFB retail investors conference, Ghent, Belgium – Meetings on 30 Sep 2017

> European Large & Midcap Event, Paris, France – Meetings on 4 Oct 2017 & 5 Oct 2017

Additional investor meetings and presentations will be announced in due time.

Earlier this week, ThromboGenics announced that it regained the full global rights to JETREA® from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of JETREA make ThromboGenics a better fit for building a sustainable long-term niche business. Under the terms of the agreement, ThromboGenics received a cash amount of €53.7 million and a forthcoming Novartis equity investment of €10 million in ThromboGenics capital.

As a result of this agreement, ThromboGenics now holds a cash position of over €120 million.

ThromboGenics has developed a world class pipeline of disease modifying drug candidates for the treatment of diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edma (DMA). The current drug development pipeline includes THR-409 (ocriplasmin), THR-317 (anti-PlGF), THR-149 (plasma kallikrein inhibitor), and THR-687 (integrin receptor antagonist). The company has different additional compounds and pathways in the discovery phase.


For further information please contact:

Wouter Piepers, Global Head of Corporate Communications & IR
+32 16 75 13 10 / +32 478 33 56 32

Citigate Dewe Rogerson
David Dible/ Sylvie Berrebi / Isabelle Andrews
Tel: +44 20 7638 9571

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for eye disease, with a focus on diabetic eye disease. The company’s pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is conducting a Phase IIa clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with NonProliferative Diabetic Retinopathy (NPDR).

ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a PLGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic vitreomacular traction in 54 countries worldwide.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume an obligation to update or revise any forwardlooking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Record changed: 2017-10-06


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Oxurion (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top